

Yogen Saunthararajah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7064509/publications.pdf>

Version: 2024-02-01

115
papers

5,134
citations

136740

32
h-index

91712

69
g-index

117
all docs

117
docs citations

117
times ranked

6073
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia. JAMA - Journal of the American Medical Association, 2003, 289, 1645.	3.8	741
2	Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood, 2009, 113, 1315-1325.	0.6	378
3	Dynamics of clonal evolution in myelodysplastic syndromes. Nature Genetics, 2017, 49, 204-212.	9.4	348
4	Effects of 5-aza-2-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood, 2003, 102, 3865-3870.	0.6	262
5	HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood, 2002, 100, 1570-1574.	0.6	235
6	Modification of hematopoietic stem cell fate by 5-aza-2-deoxycytidine and trichostatin A. Blood, 2004, 103, 4102-4110.	0.6	198
7	Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood, 2008, 111, 3991-3997.	0.6	193
8	SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood, 2012, 120, 3173-3186.	0.6	173
9	Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood, 2001, 98, 3513-3519.	0.6	135
10	Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy. Clinical Cancer Research, 2013, 19, 938-948.	3.2	115
11	Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study. PLoS Medicine, 2017, 14, e1002382.	3.9	107
12	Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. Journal of Clinical Investigation, 2018, 128, 4260-4279.	3.9	97
13	Methylation Profiles Reveal Distinct Subgroup of Hepatocellular Carcinoma Patients with Poor Prognosis. PLoS ONE, 2014, 9, e104158.	1.1	94
14	Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood, 2012, 119, 1240-1247.	0.6	90
15	Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. Journal of Clinical Investigation, 2015, 125, 1043-1055.	3.9	79
16	HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood, 2002, 100, 1570-4.	0.6	75
17	The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice. Blood, 2015, 126, 386-396.	0.6	74
18	A pilot study of subcutaneous decitabine in β^0 -thalassemia intermedia. Blood, 2011, 118, 2708-2711.	0.6	73

#	ARTICLE	IF	CITATIONS
19	Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes. Hematology American Society of Hematology Education Program, 2013, 2013, 511-521.	0.9	70
20	Prospective Clinical Study of Precision Oncology in Solid Tumors. Journal of the National Cancer Institute, 2016, 108, .	3.0	70
21	A Novel <scp> </scp>-Asparaginase with low <scp> </scp>-Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias <i>In Vivo</i>. Cancer Research, 2018, 78, 1549-1560.	0.4	67
22	Epigenetic regulation by decitabine of melanoma differentiation <i>in vitro</i> and <i>in vivo</i>. International Journal of Cancer, 2012, 131, 18-29.	2.3	64
23	Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells. Cell Death and Disease, 2018, 9, 912.	2.7	64
24	Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network. Leukemia, 2021, 35, 1023-1036.	3.3	62
25	OAS-RNase L innate immune pathway mediates the cytotoxicity of a DNA-demethylating drug. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 5071-5076.	3.3	58
26	High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. Oncotarget, 2012, 3, 1137-1145.	0.8	53
27	p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies. Seminars in Oncology, 2012, 39, 97-108.	0.8	51
28	Decitabine Maintains Hematopoietic Precursor Self-Renewal by Preventing Repression of Stem Cell Genes by a Differentiation-Inducing Stimulus. Molecular Cancer Therapeutics, 2010, 9, 1536-1543.	1.9	50
29	RUNX1 regulates corepressor interactions of PU.1. Blood, 2011, 117, 6498-6508.	0.6	49
30	The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis). Haematologica, 2016, 101, 688-697.	1.7	48
31	GSK-3 Inhibition Sensitizes Acute Myeloid Leukemia Cells to 1,25D-Mediated Differentiation. Cancer Research, 2016, 76, 2743-2753.	0.4	43
32	Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. Cancer Discovery, 2019, 9, 778-795.	7.7	41
33	Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression. Leukemia, 2021, 35, 2799-2812.	3.3	41
34	Fetal Hemoglobin Induction by Epigenetic Drugs. Seminars in Hematology, 2018, 55, 60-67.	1.8	35
35	GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition. Journal of Clinical Investigation, 2017, 127, 3527-3542.	3.9	35
36	Recurrent genetic defects on chromosome 5q in myeloid neoplasms. Oncotarget, 2017, 8, 6483-6495.	0.8	34

#	ARTICLE	IF	CITATIONS
37	DNA hypo-methylating agents and sickle cell disease. <i>British Journal of Haematology</i> , 2004, 126, 629-636.	1.2	33
38	Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1441-1450.	2.0	33
39	Runx1 Regulation of Pu.1 Corepressor/Coactivator Exchange Identifies Specific Molecular Targets for Leukemia Differentiation Therapy. <i>Journal of Biological Chemistry</i> , 2014, 289, 14881-14895.	1.6	33
40	Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. <i>Leukemia</i> , 2020, 34, 957-962.	3.3	32
41	Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1885-1895.	0.6	32
42	Noncytotoxic Differentiation Treatment of Renal Cell Cancer. <i>Cancer Research</i> , 2011, 71, 1431-1441.	0.4	30
43	Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia. <i>Communications Biology</i> , 2020, 3, 493.	2.0	30
44	iTRAQ Quantitative Proteomic Comparison of Metastatic and Non-Metastatic Uveal Melanoma Tumors. <i>PLoS ONE</i> , 2015, 10, e0135543.	1.1	27
45	The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders. <i>Blood</i> , 2021, 138, 2781-2798.	0.6	27
46	Functional analyses of human LUC7-like proteins involved in splicing regulation and myeloid neoplasms. <i>Cell Reports</i> , 2021, 35, 108989.	2.9	23
47	Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts. <i>Journal of Hematology and Oncology</i> , 2014, 7, 89.	6.9	22
48	Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine. <i>Leukemia and Lymphoma</i> , 2014, 55, 447-449.	0.6	19
49	Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts. <i>Leukemia and Lymphoma</i> , 2015, 56, 497-499.	0.6	19
50	Ligand exchange on gold nanoparticles for drug delivery and enhanced therapeutic index evaluated in acute myeloid leukemia models. <i>Experimental Biology and Medicine</i> , 2014, 239, 853-861.	1.1	18
51	Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons. <i>Experimental Hematology</i> , 2018, 67, 60-64.e2.	0.2	17
52	Targeting sickle cell disease root-cause pathophysiology with small molecules. <i>Haematologica</i> , 2019, 104, 1720-1730.	1.7	15
53	Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies. <i>British Journal of Haematology</i> , 2020, 188, 924-929.	1.2	15
54	Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	15

#	ARTICLE	IF	CITATIONS
55	Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 574-582.	1.9	14
56	Subchronic Oral Toxicity Study of Decitabine in Combination With Tetrahydrouridine in CD-1 Mice. <i>International Journal of Toxicology</i> , 2014, 33, 75-85.	0.6	13
57	Ultimate Precision: Targeting Cancer but Not Normal Self-replication. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 950-963.	1.8	13
58	Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion. <i>Scientific Reports</i> , 2019, 9, 4558.	1.6	13
59	Polycomb segment myeloid malignancies. <i>Blood</i> , 2012, 119, 1097-1098.	0.6	12
60	Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 812-824.	1.8	12
61	Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 2649.	1.7	12
62	Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions. <i>Clinical Cancer Research</i> , 2021, 27, 6653-6661.	3.2	12
63	Thioredoxin reductase is a major regulator of metabolism in leukemia cells. <i>Oncogene</i> , 2021, 40, 5236-5246.	2.6	11
64	Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen. <i>Clinical Case Reports (discontinued)</i> , 2017, 5, 2025-2027.	0.2	10
65	EZH2 Inhibitors: Take It EZy, It Is All About Context. <i>Cancer Discovery</i> , 2019, 9, 472-475.	7.7	10
66	Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1122-1127.	2.0	10
67	Standard clinical practice underestimates the role and significance of erythropoietin deficiency in sickle cell disease. <i>British Journal of Haematology</i> , 2011, 153, 386-392.	1.2	9
68	PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiation. <i>Cell Reports</i> , 2021, 36, 109747.	2.9	9
69	Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 812-824.	1.8	9
70	Prognostic Factors for Post-Transplant Outcomes in Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2011, 118, 2015-2015.	0.6	9
71	CEBPE activation in PML-RARA cells by arsenic. <i>Blood</i> , 2012, 119, 2177-2179.	0.6	8
72	Gender, Cytidine Deaminase, and 5-Aza/Decitabine Response. <i>Clinical Cancer Research</i> , 2013, 19, 3106-3107.	3.2	8

#	ARTICLE	IF	CITATIONS
73	DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>Seminars in Hematology</i> , 2021, 58, 45-55.	1.8	8
74	5-aza-2,2-Difluoro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of Cancer. <i>Pharmaceuticals</i> , 2017, 10, 65.	1.7	7
75	A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies. <i>Seminars in Hematology</i> , 2021, 58, 35-44.	1.8	7
76	The Role of LUC7L2 in Splicing and MDS. <i>Blood</i> , 2016, 128, 5504-5504.	0.6	7
77	Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation. <i>Haematologica</i> , 2020, 105, 2191-2193.	1.7	6
78	Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas. <i>International Journal of Cancer</i> , 2022, 151, 1431-1446.	2.3	6
79	Ribosomal S6 Kinase and AKT Phosphorylation as Pharmacodynamic Biomarkers in Patients With Myelodysplastic Syndrome Treated With RAD001. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 172-177.e1.	0.2	5
80	Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. <i>Leukemia and Lymphoma</i> , 2021, 62, 735-738.	0.6	5
81	Decitabine Suspends Human CD34+ Cell Differentiation and Proliferation during Lentiviral Transduction. <i>PLoS ONE</i> , 2014, 9, e104022.	1.1	4
82	[18F] Clofarabine for PET Imaging of Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1748.	1.7	4
83	Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation. <i>Annals of Hematology</i> , 2019, 98, 1529-1531.	0.8	4
84	Epigenetic modifier directed therapeutics to unleash healthy genes in unhealthy cells. <i>Seminars in Hematology</i> , 2021, 58, 1-3.	1.8	4
85	CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas. <i>Blood Cancer Journal</i> , 2019, 9, 14.	2.8	3
86	A non-cytotoxic regimen of decitabine to treat refractory T-cell large granular lymphocytic leukemia. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04533.	0.2	3
87	Combination with Thu to Address Pharmacologic Limitations of Decitabine, Interim PK/PD from a Phase 1/2 Clinical Trial of Oral Thu-Decitabine in Sickle Cell Disease. <i>Blood</i> , 2014, 124, 90-90.	0.6	3
88	Differences Between Normal and Leukemic Stem Cell-Specific Methylome Indicates Aberrantly Silenced Genes Involved in the Pathogenesis of Malignant Evolution. <i>Blood</i> , 2008, 112, 599-599.	0.6	3
89	A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer. <i>American Journal of Cancer Research</i> , 2020, 10, 3047-3060.	1.4	3
90	Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations. <i>Leukemia</i> , 2021, 35, 3324-3328.	3.3	2

#	ARTICLE	IF	CITATIONS
91	Î²-Hemoglobinopathies lead the way. <i>Blood</i> , 2021, 137, 1567-1569.	0.6	2
92	Serial Sequencing in Myelodysplastic Syndromes Reveals Dynamic Changes in Clonal Architecture and Allows for a New Prognostic Assessment of Mutations Detected in Cross-Sectional Testing. <i>Blood</i> , 2015, 126, 709-709.	0.6	2
93	Functional characterization of NPM1-TYK2 fusion oncogene. <i>Npj Precision Oncology</i> , 2022, 6, 3.	2.3	2
94	p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. <i>Nature Precedings</i> , 2011, , .	0.1	1
95	Cytoplasmic dislocation of NPM1 and PU.1 in NPM1 mutated leukaemia is obscured by paraformaldehyde fixation. <i>British Journal of Haematology</i> , 2020, 189, 578-581.	1.2	1
96	Race and Intensity of Post-Remission Therapy in Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2009, 114, 1012-1012.	0.6	1
97	Splicing Factor 3b Subunit 1 (SF3B1) mediates Mitochondrial Iron Overload In Myelodysplastic Syndromes With Ring Sideroblasts By Alternative Splicing Of Mitoferrin-1 (SLC25A37). <i>Blood</i> , 2013, 122, 1555-1555.	0.6	1
98	A phase I/II trial of very low to low-dose continuous azacitidine in combination with standard doses of lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8584-8584.	0.8	1
99	Liver background uptake of [F]FLT in PET imaging. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 10, 212-225.	1.0	1
100	Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia. <i>Leukemia</i> , 2021, , .	3.3	1
101	Gender effects on cytidine analogue metabolism and myelodysplastic syndrome treatment outcomes. <i>Nature Precedings</i> , 2012, , .	0.1	0
102	Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis. <i>Cancer Discovery</i> , 2019, , .	7.7	0
103	Runx1 Deficiency Produces Aberrant Progenitor Self-Renewal through Selective Compromise of Pu.1 Mediated Transactivation but Not Transrepression.. <i>Blood</i> , 2008, 112, 1351-1351.	0.6	0
104	The Value of Post-Remission Therapy in Older Adults with Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2009, 114, 1043-1043.	0.6	0
105	Strong Histone (H4) Acetylation Is Independently Associated with Better Overall Survival in Newly Diagnosed Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2009, 114, 4681-4681.	0.6	0
106	A High Resolution Analysis of Chromosome 21 Amplification In Myeloid Malignancies Reveals An Association with a Specific Cytogenetic Subgroup and Enhanced ERG Gene Expression.. <i>Blood</i> , 2010, 116, 1687-1687.	0.6	0
107	Identification of Oncogenic EZH2 Mutations In Myelodysplastic Syndromes and Related Myeloid Malignancies. <i>Blood</i> , 2010, 116, 607-607.	0.6	0
108	Expression of Phosphorylated Signal Transducer and Activator of Transcription 5 (pSTAT5) Is Associated with An Increased Risk of Death In Acute Myeloid Leukemia.. <i>Blood</i> , 2010, 116, 1675-1675.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Prognostic Significance of Histone (H4) Acetylation In Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with Intermediate Risk Cytogenetics. <i>Blood</i> , 2010, 116, 2736-2736.	0.6	0
110	Combining Tetrahydrouridine with Decitabine Addresses Malignant Cell Sanctuary in the Liver, a Tissue That Expresses High Levels of Cytidine Deaminase,. <i>Blood</i> , 2011, 118, 3509-3509.	0.6	0
111	Radiation Treatment for Localized Prostate Cancer and the Risk of Developing Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2011, 118, 120-120.	0.6	0
112	Runx1 Haploinsufficiency Permits Lineage-Commitment but Impairs Activation of a Key Late Differentiation Gene. <i>Blood</i> , 2011, 118, 2442-2442.	0.6	0
113	Oral Administration of Low-Dose Decitabine and Tetrahydrouridine In Combination Increases Fetal Hemoglobin to Therapeutic Levels In the Absence of Cytotoxicity and Reduces Inter-Individual Drug Bioavailability In Baboons. <i>Blood</i> , 2011, 118, 2147-2147.	0.6	0
114	Pre-clinical proof of principle of pharmacologically rational non-cytotoxic epigenetic-immunotherapy to treat lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14073-e14073.	0.8	0
115	Low-dose weekly decitabine and venetoclax in <i>TP53</i> -mutated myeloid malignancies.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19005-e19005.	0.8	0